Compile Data Set for Download or QSAR
Report error Found 24 Enz. Inhib. hit(s) with all data for entry = 12302
TargetTGF-beta receptor type-1(Human)
Clavius Pharmaceuticals

US Patent
LigandPNGBDBM694365(US12077548, Compound 96)
Affinity DataIC50: 1.70nMAssay Description:Exemplified compounds are screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM or at single concentrations...More data for this Ligand-Target Pair
Ligand InfoSimilars
In DepthDetails
US Patent

TargetTGF-beta receptor type-1(Human)
Clavius Pharmaceuticals

US Patent
LigandPNGBDBM694349(US12077548, Compound 24)
Affinity DataIC50: 1.80nMAssay Description:Exemplified compounds are screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM or at single concentrations...More data for this Ligand-Target Pair
Ligand InfoSimilars
In DepthDetails
US Patent

TargetTGF-beta receptor type-1(Human)
Clavius Pharmaceuticals

US Patent
LigandPNGBDBM694359(US12077548, Compound 90)
Affinity DataIC50: 2.5nMAssay Description:Exemplified compounds are screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM or at single concentrations...More data for this Ligand-Target Pair
Ligand InfoSimilars
In DepthDetails
US Patent

TargetTGF-beta receptor type-1(Human)
Clavius Pharmaceuticals

US Patent
LigandPNGBDBM694358(US12077548, Compound 89)
Affinity DataIC50: 2.5nMAssay Description:Exemplified compounds are screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM or at single concentrations...More data for this Ligand-Target Pair
Ligand InfoSimilars
In DepthDetails
US Patent

TargetTGF-beta receptor type-1(Human)
Clavius Pharmaceuticals

US Patent
LigandPNGBDBM694345(US12077548, Compound 16)
Affinity DataIC50: 2.60nMAssay Description:Exemplified compounds are screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM or at single concentrations...More data for this Ligand-Target Pair
Ligand InfoSimilars
In DepthDetails
US Patent

TargetTGF-beta receptor type-1(Human)
Clavius Pharmaceuticals

US Patent
LigandPNGBDBM694351(US12077548, Compound 26)
Affinity DataIC50: 3.10nMAssay Description:Exemplified compounds are screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM or at single concentrations...More data for this Ligand-Target Pair
Ligand InfoSimilars
In DepthDetails
US Patent

TargetTGF-beta receptor type-1(Human)
Clavius Pharmaceuticals

US Patent
LigandPNGBDBM694344(US12077548, Compound 8)
Affinity DataIC50: 3.30nMAssay Description:Exemplified compounds are screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM or at single concentrations...More data for this Ligand-Target Pair
Ligand InfoSimilars
In DepthDetails
US Patent

TargetTGF-beta receptor type-1(Human)
Clavius Pharmaceuticals

US Patent
LigandPNGBDBM694348(US12077548, Compound 23)
Affinity DataIC50: 5.20nMAssay Description:Exemplified compounds are screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM or at single concentrations...More data for this Ligand-Target Pair
Ligand InfoSimilars
In DepthDetails
US Patent

TargetTGF-beta receptor type-1(Human)
Clavius Pharmaceuticals

US Patent
LigandPNGBDBM694343(US12077548, Compound 7)
Affinity DataIC50: 5.5nMAssay Description:Exemplified compounds are screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM or at single concentrations...More data for this Ligand-Target Pair
Ligand InfoSimilars
In DepthDetails
US Patent

TargetTGF-beta receptor type-1(Human)
Clavius Pharmaceuticals

US Patent
LigandPNGBDBM694346(US12077548, Compound 18)
Affinity DataIC50: 6.70nMAssay Description:Exemplified compounds are screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM or at single concentrations...More data for this Ligand-Target Pair
Ligand InfoSimilars
In DepthDetails
US Patent

TargetTGF-beta receptor type-1(Human)
Clavius Pharmaceuticals

US Patent
LigandPNGBDBM694347(US12077548, Compound 22)
Affinity DataIC50: 7.20nMAssay Description:Exemplified compounds are screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM or at single concentrations...More data for this Ligand-Target Pair
Ligand InfoSimilars
In DepthDetails
US Patent

TargetTGF-beta receptor type-1(Human)
Clavius Pharmaceuticals

US Patent
LigandPNGBDBM694350(US12077548, Compound 25)
Affinity DataIC50: 7.20nMAssay Description:Exemplified compounds are screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM or at single concentrations...More data for this Ligand-Target Pair
Ligand InfoSimilars
In DepthDetails
US Patent

TargetTGF-beta receptor type-1(Human)
Clavius Pharmaceuticals

US Patent
LigandPNGBDBM694364(US12077548, Compound 95)
Affinity DataIC50: 8.90nMAssay Description:Exemplified compounds are screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM or at single concentrations...More data for this Ligand-Target Pair
Ligand InfoSimilars
In DepthDetails
US Patent

TargetTGF-beta receptor type-1(Human)
Clavius Pharmaceuticals

US Patent
LigandPNGBDBM694361(US12077548, Compound 92)
Affinity DataIC50: 11nMAssay Description:Exemplified compounds are screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM or at single concentrations...More data for this Ligand-Target Pair
Ligand InfoSimilars
In DepthDetails
US Patent

TargetTGF-beta receptor type-1(Human)
Clavius Pharmaceuticals

US Patent
LigandPNGBDBM694366(US12077548, Compound 97)
Affinity DataIC50: 12.5nMAssay Description:Exemplified compounds are screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM or at single concentrations...More data for this Ligand-Target Pair
Ligand InfoSimilars
In DepthDetails
US Patent

TargetTGF-beta receptor type-1(Human)
Clavius Pharmaceuticals

US Patent
LigandPNGBDBM694360(US12077548, Compound 91)
Affinity DataIC50: 22nMAssay Description:Exemplified compounds are screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM or at single concentrations...More data for this Ligand-Target Pair
Ligand InfoSimilars
In DepthDetails
US Patent

TargetTGF-beta receptor type-1(Human)
Clavius Pharmaceuticals

US Patent
LigandPNGBDBM694363(US12077548, Compound 94)
Affinity DataIC50: 27nMAssay Description:Exemplified compounds are screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM or at single concentrations...More data for this Ligand-Target Pair
Ligand InfoSimilars
In DepthDetails
US Patent

TargetTGF-beta receptor type-1(Human)
Clavius Pharmaceuticals

US Patent
LigandPNGBDBM694353(US12077548, Compound 49)
Affinity DataIC50: 52nMAssay Description:Exemplified compounds are screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM or at single concentrations...More data for this Ligand-Target Pair
Ligand InfoSimilars
In DepthDetails
US Patent

TargetTGF-beta receptor type-1(Human)
Clavius Pharmaceuticals

US Patent
LigandPNGBDBM694357(US12077548, Compound 88)
Affinity DataIC50: 55nMAssay Description:Exemplified compounds are screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM or at single concentrations...More data for this Ligand-Target Pair
Ligand InfoSimilars
In DepthDetails
US Patent

TargetTGF-beta receptor type-1(Human)
Clavius Pharmaceuticals

US Patent
LigandPNGBDBM694355(US12077548, Compound 75)
Affinity DataIC50: 66nMAssay Description:Exemplified compounds are screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM or at single concentrations...More data for this Ligand-Target Pair
Ligand InfoSimilars
In DepthDetails
US Patent

TargetTGF-beta receptor type-1(Human)
Clavius Pharmaceuticals

US Patent
LigandPNGBDBM694354(US12077548, Compound 50)
Affinity DataIC50: 90nMAssay Description:Exemplified compounds are screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM or at single concentrations...More data for this Ligand-Target Pair
Ligand InfoSimilars
In DepthDetails
US Patent

TargetTGF-beta receptor type-1(Human)
Clavius Pharmaceuticals

US Patent
LigandPNGBDBM694352(US12077548, Compound 28)
Affinity DataIC50: 107nMAssay Description:Exemplified compounds are screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM or at single concentrations...More data for this Ligand-Target Pair
Ligand InfoSimilars
In DepthDetails
US Patent

TargetTGF-beta receptor type-1(Human)
Clavius Pharmaceuticals

US Patent
LigandPNGBDBM694356(US12077548, Compound 86)
Affinity DataIC50: 129nMAssay Description:Exemplified compounds are screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM or at single concentrations...More data for this Ligand-Target Pair
Ligand InfoSimilars
In DepthDetails
US Patent

TargetTGF-beta receptor type-1(Human)
Clavius Pharmaceuticals

US Patent
LigandPNGBDBM694362(US12077548, Compound 93)
Affinity DataIC50: 244nMAssay Description:Exemplified compounds are screened in 1% DMSO (final concentration) by 3-fold serial dilutions from 10,000 nM to 0.316 nM or at single concentrations...More data for this Ligand-Target Pair
Ligand InfoSimilars
In DepthDetails
US Patent